Cubicin and Hepatic function abnormal - a phase IV clinical study of FDA data

Summary:

Hepatic function abnormal is reported as a side effect among people who take Cubicin (daptomycin), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Vancomycin, and have Endocarditis.

The phase IV clinical study analyzes which people have Hepatic function abnormal when taking Cubicin. It is created by eHealthMe based on reports of 7,953 people who have side effects when taking Cubicin from the FDA, and is updated regularly.

What is Cubicin?

Cubicin has active ingredients of daptomycin. It is often used in infection. eHealthMe is studying from 7,991 Cubicin users. Check the latest studies of Cubicin.

What is Hepatic function abnormal?

Hepatic function abnormal is found to be associated with 1,439 drugs and 2,020 conditions by eHealthMe. Check the latest studies of Hepatic function abnormal.

On Jul, 11, 2026

7,953 people reported to have side effects when taking Cubicin.
Among them, 74 people (0.93%) have Hepatic function abnormal.

Could Cubicin cause Hepatic function abnormal?

Among these 74 people:

How long have people been on Cubicin when they have Hepatic function abnormal? *

What is the gender of people who have Hepatic function abnormal when taking Cubicin? *

female: 30.51 %
male: 69.49 %

What is the age of people who have Hepatic function abnormal when taking Cubicin? *

What are other drugs people take besides Cubicin? *

What are other side effects people have besides Hepatic function abnormal? *

Renal Impairment (severely reduced kidney function): 20 people, 27.03%
Fever: 12 people, 16.22%
Rashes (redness): 11 people, 14.86%
Sepsis (a severe blood infection that can lead to organ failure and death): 11 people, 14.86%
Pneumonia: 10 people, 13.51%
Thrombocytopenia (decrease of platelets in blood): 9 people, 12.16%
Drug Ineffective: 8 people, 10.81%
Hypotension (abnormally low blood pressure): 7 people, 9.46%
Blood Creatinine Increased: 7 people, 9.46%
White Blood Cell Count Decreased: 6 people, 8.11%

What are the existing conditions these people have? *

Endocarditis (inflammation in heart muscle): 10 people, 13.51%
High Blood Pressure: 9 people, 12.16%
Sepsis (a severe blood infection that can lead to organ failure and death): 8 people, 10.81%
Staphylococcal Infection (an infection with staphylococcus bacteria): 8 people, 10.81%
Fever: 7 people, 9.46%
Gastric Ulcer (stomach ulcer): 5 people, 6.76%
Insomnia (sleeplessness): 5 people, 6.76%
Diabetes: 5 people, 6.76%
Multiple Myeloma (cancer of the plasma cells): 4 people, 5.41%
Prothrombin Level Decreased: 4 people, 5.41%

* Approximation only. Some reports may have incomplete information.

Do you take Cubicin and have Hepatic function abnormal?

- Check whether Hepatic function abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cubicin:

Cubicin (7,991 reports)

Browse all side effects of Cubicin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic function abnormal:

Hepatic function abnormal (1,439 drugs)

Browse all the conditions that are associated with Hepatic function abnormal:

Hepatic function abnormal (2,020 conditions)

Related publications that referenced our studies

Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .
Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on daptomycin (the active ingredients of Cubicin) and Cubicin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.